Community‐acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large‐scale, real‐world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA‐EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS‐CoV‐2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.

中文翻译：

---

2023-2024 年秋冬北方血液系统恶性肿瘤患者的呼吸道病毒：EPICOVIDEHA-EPIFLUEHA 报告


社区获得性呼吸道病毒感染 （CARV） 对血液系统恶性肿瘤 （HM） 患者有重大影响，导致高发病率和死亡率。然而，这些患者 CARV 的大规模、真实世界数据是有限的。本研究分析了来自 EPICOVIDEHA-EPIFLUEHA 登记处的数据，重点关注 2023-2024 年秋冬季被诊断患有 CARV 的 HM 患者。该研究评估了流行病学、临床特征、风险因素和结果。该研究在 1312-2023 年秋冬季检查了 2024 名被诊断患有 CARV 的 HM 患者。其中，59.5% 需要住院治疗，13.5% 需要入住 ICU。总死亡率为 10.6%，因病毒而异：副流感 （21.3%）、流感 （8.8%）、偏肺病毒 （7.1%）、RSV （5.9%） 或 SARS-CoV-2 （5.0%）。不良结局与吸烟史、严重淋巴细胞减少、继发性细菌感染和 ICU 入住显著相关。本研究强调了 CARV 对 HM 患者构成的严重风险，尤其是那些接受积极治疗的患者。高住院率和死亡率强调了更好地预防、早期诊断和靶向治疗的必要性。鉴于副流感等某些病毒的严重后果，量身定制的策略对于改善未来 CARV 季节的患者预后至关重要。